Pardes Biosciences, Inc.
Index- P/E- EPS (ttm)-1.49 Insider Own0.40% Shs Outstand58.38M Perf Week-7.58%
Market Cap100.47M Forward P/E- EPS next Y-2.04 Insider Trans322.60% Shs Float51.56M Perf Month27.08%
Income-86.80M PEG- EPS next Q-0.51 Inst Own76.70% Short Float / Ratio5.69% / 9.75 Perf Quarter40.77%
Sales- P/S- EPS this Y-196.20% Inst Trans0.94% Short Interest2.93M Perf Half Y-39.20%
Book/sh3.46 P/B0.53 EPS next Y-15.90% ROA-35.50% Target Price10.33 Perf Year-84.79%
Cash/sh3.81 P/C0.48 EPS next 5Y- ROE-37.00% 52W Range0.75 - 13.01 Perf YTD8.28%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-85.93% Beta-
Dividend %- Quick Ratio17.80 Sales past 5Y- Gross Margin- 52W Low144.00% ATR0.24
Employees30 Current Ratio17.80 Sales Q/Q- Oper. Margin- RSI (14)53.79 Volatility12.37% 14.32%
OptionableNo Debt/Eq0.00 EPS Q/Q-3.20% Profit Margin- Rel Volume1.33 Prev Close1.71
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume300.71K Price1.83
Recom1.30 SMA20-1.28% SMA5029.28% SMA200-42.29% Volume401,237 Change7.02%
Mar-15-22Initiated SVB Leerink Outperform
Jan-18-22Initiated Jefferies Buy $25
Nov-07-22 04:01PM
Nov-01-22 08:30AM
Sep-14-22 08:00AM
Sep-13-22 08:00AM
Sep-12-22 08:30AM
08:00AM Loading…
Aug-15-22 08:00AM
Jul-24-22 10:21AM
Jun-06-22 06:15AM
Jun-01-22 08:30AM
May-10-22 04:01PM
Apr-21-22 12:00PM
Mar-29-22 04:05PM
Mar-21-22 07:00AM
Mar-04-22 04:30PM
Mar-03-22 07:00AM
04:30PM Loading…
Mar-02-22 04:30PM
Feb-14-22 07:30AM
Feb-09-22 07:00AM
Feb-08-22 07:00AM
Feb-07-22 05:38PM
Feb-03-22 07:00AM
Jan-05-22 07:00AM
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Brusky Sean P.Chief Commercial OfficerDec 08Buy1.1921,00024,99021,000Dec 12 04:02 PM
WIGGANS THOMAS GChief Executive OfficerDec 05Buy1.0912,50013,62550,000Dec 07 04:29 PM
WIGGANS THOMAS GChief Executive OfficerDec 02Buy1.0712,50013,37537,500Dec 05 04:21 PM
Foresite Capital Management V,10% OwnerDec 01Buy0.85637,420541,80712,809,810Dec 05 04:24 PM
WIGGANS THOMAS GChief Executive OfficerDec 01Buy1.0425,00026,00025,000Dec 05 04:21 PM